ASC2ESCALATE: A US Phase 2, Open-Label, Single-Arm, Dose-Escalation Study of Asciminib (ASC) Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) As Second-Line (2L) and First-Line (1L) Treatment
Authors: Atallah Ehab L. , Mauro Michael , Sasaki Koji , Levy Moshe , Koller Paul B. , Yang Daisy , Laine Dramane , Sabo John , GU Ennan , Cortes Jorge 
Published: December 2023

CONCLUSIONS

Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitors (TKIs) have increased survival in CML, although resistance and intolerance remain challenges, which often necessitate switch to another TKI. Many pts discontinue 1L treatment due to resistance/intolerance and switch to 2L therapy, to which resistance is typically higher. A need exists for effective, safe treatment options for pts in 1L and 2L. ASC is thefirst approved BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP), with activity against most BCR::ABL1 kinase domain mutations conferring resistance to ATP-competitive TKIs, potentially providing a new early-line treatment option.

ASC was first approved in the United States for pts with CML-CP after ≥2 TKIs at 80 mg once daily (QD) or 40 mg twice daily (BID) and for pts with CML-CP with the T315I mutation at 200 mg BID. A large, phase 1, dose-escalation trial (NCT02081378) demonstrated efficacy and tolerability of ASC across a broad range of dosages. Also, with &gt;2 years of follow-up, ASC demonstrated superior efficacy and better safety and tolerability compared with bosutinib in pts with CML-CP without the T315I mutation after ≥2 prior TKIs in the phase 3 ASCEMBL study (NCT03106779). We describe the phase 2 ASC2ESCALATE trial investigating efficacy and safety of ASC with dose escalation in pts with CML-CP receiving ASC as their 2L or 1L therapy.

This is a phase 2, open-label, multicenter, single-arm, dose-escalation study with sites in the United States (NCT05384587) (Figure). Pts receiving ASC as their 2L TKI must be adults with non-T315I CML-CP who discontinued their first ATP-competitive TKI for warning response ( BCR::ABL1IS &gt;1%-10% after 6 months or &gt;0.1%-1% after 12 months of 1L treatment), resistance ( BCR::ABL1IS &gt;10% after 6-12 months or &gt;1% or loss of major molecular response [MMR] after &gt;12 months of 1L treatment), or intolerance (with BCR::ABL1IS &gt;0.1% at screening). In addition to pts receiving ASC as their 2L TKI, a separate cohort of newly diagnosed pts will be included, and these pts may receive up to 4 weeks of prior treatment with imatinib or an approved second-generation TKI (Table).

All pts will start treatment with ASC 80 mg QD. Pts achieving BCR::ABL1IS ≤1% at 6 months will continue at the same dose; pts not achieving BCR::ABL1IS ≤1% at 6 months will have their dose escalated to 200 mg QD. In pts not achieving MMR at 12 months, dose escalation from 80 to 200 mg QD or from 200 mg QD to 200 mg BID will occur or the pt will be taken off the study. If pts have grade ≥3 or persistent grade 2 toxicity refractory to optimal management, no dose escalation will occur, and pts will remain on ASC at their most current dose. This dose-escalation strategy applies to both the 2L and 1L cohorts.

The primary endpoint is MMR rate at 12 months in pts using ASC as their 2L TKI. As all primary and secondary endpoints for the 2L cohort will be measured for the 1L cohort as secondary endpoints, the MMR rate at 12 months in pts receiving ASC as their 1L TKI is a secondary endpoint. Additional secondary endpoints are the same for both 2L and 1L cohorts and include MMR rates at 3, 6, 18, and 24 months; MMR rates by all scheduled time points; MR 2 ( BCR::ABL1IS ≤1%), MR 4 ( BCR::ABL1IS ≤0.01%), and MR 4.5 ( BCR::ABL1IS ≤0.0032%) at and by scheduled time points; time to and duration of MMR; time to treatment failure; progression-free survival; overall survival; and safety/tolerability. Exploratory endpoints include assessment of BCR::ABL1 mutations.

ASC2ESCALATE is the first clinical trial designed to assess pts with CML-CP using ASC as their 2L TKI and will provide critical information on efficacy and safety of dose escalation in pts for whom certain response milestones are not met in 2L and 1L. Dose escalation of ASC in 2L and 1L is another treatment strategy and results from ASC2ESCALATE will add to the growing body of evidence for using ASC to treat pts with CML-CP. Recruitment for pts using ASC as their 2L TKI began November 2022, and as of July 10, 2023, 5 pts have been enrolled in this cohort; Up to 92 and 90 pts are estimated to enroll in the 2L and 1L cohorts, respectively, across 90 sites.